Stoke Therapeutics (NASDAQ:STOK) Director Sells $22,264.00 in Stock

March 18, 2026 by InsiderTrades.com

Key Points

Director sale: Director Arthur Levin sold 605 shares at an average price of $36.80 for a $22,264 transaction, reducing his stake to 4,237 shares — a ~12.49% ownership decrease.
Disappointing quarterly results: Stoke reported an EPS loss of ($0.97) vs. consensus ($0.75) and revenue of $1.4M vs. $5.32M expected, a miss that could pressure the stock.
Analyst outlook still positive: Despite the miss, Wall Street maintains a generally favorable view with a "Moderate Buy" consensus and an average price target around $39.83 after several target increases.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Arthur Levin sold 605 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $36.80, for a total transaction of $22,264.00. Following the transaction, the director directly owned 4,237 shares in the company, valued at approximately $155,921.60. This trade represents a 12.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK opened at $32.87 on Wednesday. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $40.22. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of 49.06 and a beta of 1.07. The business has a 50-day moving average of $32.69 and a 200-day moving average of $29.89.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.22). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The firm had revenue of $1.40 million for the quarter, compared to analysts' expectations of $5.32 million. Research analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a research report on Monday, January 5th. Wedbush upped their price target on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an "outperform" rating in a research report on Tuesday. Weiss Ratings restated a "hold (c-)" rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Canaccord Genuity Group boosted their price target on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, January 5th. Finally, Wolfe Research started coverage on Stoke Therapeutics in a research note on Monday, February 23rd. They issued an "outperform" rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $39.83.

Get Our Latest Analysis on Stoke Therapeutics

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

Positive Sentiment: Analysts raised targets and ratings — Needham raised its price target from $35 to $40 and maintains a "buy" rating; Wedbush raised its target from $36 to $38 and keeps an "outperform" rating, signaling continued analyst confidence and potential upside. Analyst Price Target Raises
Neutral Sentiment: Company granted inducement stock options (58,650 options to six new hires effective March 16, 2026) — this helps recruit talent but adds potential future dilution. Inducement Grants Release
Negative Sentiment: Quarterly results missed expectations — EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.32M expected. The revenue shortfall and wider EPS miss are the clearest drivers of downward pressure on the share price. Quarterly Earnings Report
Negative Sentiment: Insider sale — Director Arthur A. Levin sold 605 shares at an average $36.80, reducing his holdings by ~12.5%. The sale is relatively small in dollar terms but may be interpreted negatively by some investors. SEC Form 4

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds have recently bought and sold shares of the business. Kestra Advisory Services LLC purchased a new stake in shares of Stoke Therapeutics during the fourth quarter worth $26,000. Harbour Investments Inc. increased its position in Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company's stock worth $38,000 after purchasing an additional 898 shares during the last quarter. Generali Investments Management Co LLC acquired a new position in Stoke Therapeutics in the 3rd quarter worth about $41,000. BNP Paribas Financial Markets raised its stake in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock worth $48,000 after purchasing an additional 1,668 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock valued at $50,000 after buying an additional 3,591 shares during the last quarter.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.